M

Your submission is now a Draft.

Once it's ready, please submit your draft for review by our team of Community Moderators. Thank you!

You have been invited to co-author this question.

When it is ready, the author will submit it for review by Community Moderators. Thanks for helping!

Pending

This question now needs to be reviewed by Community Moderators.

We have high standards for question quality. We also favor questions on our core topic areas or that we otherwise judge valuable. We may not publish questions that are not a good fit.

If your question has not received attention within a week, or is otherwise pressing, you may request review by tagging @moderators in a comment.

You have been invited to co-author this question.

It now needs to be approved by Community Moderators. Thanks for helping!

{{qctrl.question.title}}

{{qctrl.question.predictionCount() | abbrNumber}} predictions
{{"myPredictionLabel" | translate}}:  
{{ qctrl.question.resolutionString() }}
{{qctrl.question.predictionCount() | abbrNumber}} predictions
My score: {{qctrl.question.player_log_score | logScorePrecision}}
Created by: Metaculus-Partners and
co-authors , {{coauthor.username}}
Healthy Communities Keep Virginia Safe Tournament

Make a Prediction

Prediction

It remains unclear when public health agencies in the U.S. might recommend a SARS-CoV-2 booster dose for at least some vulnerable groups of fully vaccinated Americans (e.g.,immunocompromised groups or adults over 65 years old). There are currently three vaccines authorized for emergency use in the U.S.: the two-dose Pfizer-BioNTech vaccine, the two-dose Moderna vaccine, and the single-dose Janssen vaccine.

On 8 July 2021 Pfizer and BioNTech released a statement saying they “believe that a third dose may be beneficial to maintain the highest levels of protection” — they propose that this third dose would either be another dose of the original BNT162b2 vaccine or an updated version that targets the Delta variant’s spike protein. Later on 8 July 2021, the U.S. CDC and FDA issued a joint statement saying “Americans who have been fully vaccinated do not need a booster shot at this time.” In its 28 July 2021 second quarter results, Pfizer states that “newly disclosed data demonstrates that a third dose [of the original BNT162b2 vaccine] elicits neutralizing titers against the Delta (B.1.617.2) variant that are more than five times higher in younger people and more than 11 times higher in older people than after two doses.”

Moderna co-founder Derrick Rossi has also suggested that a booster will “almost certainly” be needed. There also remains ongoing discussion as to whether recipients of the single-dose Janssen vaccine will need a second dose to serve as a booster.